Redirecting to https://markets.businessinsider.com/news/stocks/blossomhill-therapeutics-announces-fda-fast-track-designation-for-bh-30643-a-macrocyclic-omni-egfr-inhibitor-for-the-treatment-of-advanced-egfr-c797s-positive-nsclc-1036470000